BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stockley RA, Miravitlles M, Vogelmeier C; Alpha One International Registry (A.I.R.). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis 2013;8:149. [PMID: 24063809 DOI: 10.1186/1750-1172-8-149] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Stockley JA, Ismail AM, Hughes SM, Edgar R, Stockley RA, Sapey E. Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency. Eur Respir J 2017;49:1602055. [PMID: 28356373 DOI: 10.1183/13993003.02055-2016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
2 Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Antonio Riesco J, Simonet P, Rigau D, Soriano JB, Ancochea J. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol 2017;53:324-35. [PMID: 28477954 DOI: 10.1016/j.arbres.2017.03.018] [Cited by in Crossref: 237] [Cited by in F6Publishing: 214] [Article Influence: 47.4] [Reference Citation Analysis]
3 Karadagi A, Cavedon AG, Zemack H, Nowak G, Eybye ME, Zhu X, Guadagnin E, White RA, Rice LM, Frassetto AL, Strom S, Jorns C, Martini PGV, Ellis E. Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency. Sci Rep 2020;10:7052. [PMID: 32341402 DOI: 10.1038/s41598-020-64017-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Esquinas C, Serreri S, Barrecheguren M, Rodriguez E, Nuñez A, Casas-Maldonado F, Blanco I, Pirina P, Lara B, Miravitlles M. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT). Int J Chron Obstruct Pulmon Dis 2018;13:1001-7. [PMID: 29615836 DOI: 10.2147/COPD.S155226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Sucena M, Gomes J, Guimarães C, Miravitlles M. Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. Pulmonology 2020;26:181-3. [DOI: 10.1016/j.pulmoe.2020.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Guo S, Booten SL, Watt A, Alvarado L, Freier SM, Teckman JH, McCaleb ML, Monia BP. Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease. Rare Dis 2014;2:e28511. [PMID: 25054094 DOI: 10.4161/rdis.28511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
8 Esquinas C, Miravitlles M. Are There Differences Between the Available Treatments for Emphysema Associated with Alpha-1 Antitrypsin Deficiency? Arch Bronconeumol (Engl Ed) 2018;54:451-2. [PMID: 29625713 DOI: 10.1016/j.arbres.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros 2016;15:227-33. [PMID: 26321218 DOI: 10.1016/j.jcf.2015.07.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
10 Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis 2016;11:1745-56. [PMID: 27536086 DOI: 10.2147/COPD.S111508] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
11 Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F. Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidiscip Respir Med 2018;13:39. [PMID: 30338069 DOI: 10.1186/s40248-018-0153-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Hutsebaut J, Janssens W, Louis R, Willersinn F, Stephenne X, Sokal E, Derom E. Activity of the alpha-1 antitrypsin deficiency registry in Belgium. COPD 2015;12 Suppl 1:10-4. [PMID: 25938285 DOI: 10.3109/15412555.2015.1021916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114. [PMID: 29996870 DOI: 10.1186/s13023-018-0856-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 11.8] [Reference Citation Analysis]
15 Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-frías F, Torres M, Lara B. Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina. Archivos de Bronconeumología 2015;51:185-92. [DOI: 10.1016/j.arbres.2014.05.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
16 Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9-19. [PMID: 28752442 DOI: 10.1007/978-1-4939-7163-3_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Nyon MP, Gooptu B. Therapeutic targeting of misfolding and conformational change in α 1 -antitrypsin deficiency. Future Medicinal Chemistry 2014;6:1047-65. [DOI: 10.4155/fmc.14.58] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
18 Butler A, Walton GM, Sapey E. Neutrophilic Inflammation in the Pathogenesis of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease 2018;15:392-404. [DOI: 10.1080/15412555.2018.1476475] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
19 Campos M, Lascano J. Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy. Methods Mol Biol 2017;1639:249-62. [PMID: 28752465 DOI: 10.1007/978-1-4939-7163-3_25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lopes AP, Mineiro MA, Costa F, Gomes J, Santos C, Antunes C, Maia D, Melo R, Canotilho M, Magalhães E, Vicente I, Valente C, Gonçalves BG, Conde B, Guimarães C, Sousa C, Amado J, Brandão ME, Sucena M, Oliveira MJ, Seixas S, Teixeira V, Telo L. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 2018;24 Suppl 1:1-21. [PMID: 30473034 DOI: 10.1016/j.pulmoe.2018.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
21 Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. Int J Chron Obstruct Pulmon Dis 2020;15:3193-9. [PMID: 33299307 DOI: 10.2147/COPD.S263725] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Barrecheguren M, O'Hara K, Wilkens M, Boyd J, Kolda E, Lara B, Chorostowska-Wynimko J, Ferrarotti I, Chlumský J, Clarenbach C, Greulich T, Miravitlles M, Sucena M. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. [PMID: 33447613 DOI: 10.1183/23120541.00523-2020] [Reference Citation Analysis]
23 Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. Am J Respir Crit Care Med 2019;200:318-26. [PMID: 30965011 DOI: 10.1164/rccm.201901-0010OC] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 14.5] [Reference Citation Analysis]
24 Janciauskiene S, Welte T. Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments. Annals ATS 2016;13:S280-8. [DOI: 10.1513/annalsats.201507-468kv] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
25 Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-frías F, Torres M, Lara B. Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update. Archivos de Bronconeumología (English Edition) 2015;51:185-92. [DOI: 10.1016/j.arbr.2014.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Mobeen F, Edgar RG, Pye A, Stockley RA, Turner AM. Relationship between Depression and Anxiety, Health Status and Lung Function in Patients with Alpha-1 Antitrypsin Deficiency. COPD 2021;:1-9. [PMID: 34676796 DOI: 10.1080/15412555.2021.1991904] [Reference Citation Analysis]
27 Luisetti M, Ferrarotti I, Corda L, Ottaviani S, Gatta N, Tinelli C, Bruletti G, Bertella E, Balestroni G, Confalonieri M, Seebacher C, Iannacci L, Ferrari S, Salerno FG, Mariani F, Carone M, Balbi B. Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation. COPD 2015;12 Suppl 1:52-7. [PMID: 25938293 DOI: 10.3109/15412555.2015.1023393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
28 Jardim JR, Casas-Maldonado F, Fernandes FLA, Castellano MVCO, Torres-Durán M, Miravitlles M. Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. J Bras Pneumol 2021;47:e20200380. [PMID: 34076174 DOI: 10.36416/1806-3756/e20200380] [Reference Citation Analysis]
29 Miravitlles M, Soler-cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J. Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumología (English Edition) 2017;53:324-35. [DOI: 10.1016/j.arbr.2017.03.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 3.6] [Reference Citation Analysis]
30 Nuñez A, Barrecheguren M, Rodríguez E, Miravitlles M, Esquinas C. Diagnosis of alpha1-antitrypsin deficiency not just in severe COPD. Pulmonology 2018;24:351-3. [PMID: 29921528 DOI: 10.1016/j.pulmoe.2018.05.005] [Reference Citation Analysis]
31 Greulich T, Albert A, Cassel W, Boeselt T, Peychev E, Klemmer A, Ferreira F, Clarenbach C, Torres-Duran ML, Turner AM, Miravitlles M. Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. Int J Chron Obstruct Pulmon Dis 2022;17:53-64. [PMID: 35023913 DOI: 10.2147/COPD.S346051] [Reference Citation Analysis]
32 Rao L, Xu Y, Reineke LC, Bhattacharya A, Tyryshkin A, Shin JN, Eissa NT. Post-Transcriptional Regulation of Alpha One Antitrypsin by a Proteasome Inhibitor. Int J Mol Sci 2020;21:E4318. [PMID: 32560429 DOI: 10.3390/ijms21124318] [Reference Citation Analysis]
33 Campos MA, Lascano J. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Ther Adv Respir Dis 2014;8:150-61. [PMID: 25013223 DOI: 10.1177/1753465814542243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
34 Sieluk J, Levy J, Sandhaus RA, Silverman H, Holm KE, Mullins CD. Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. Chronic Obstr Pulm Dis 2018;6:6-16. [PMID: 30775420 DOI: 10.15326/jcopdf.6.1.2017.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Stockley RA. Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT): The United Kingdom Registry. COPD 2015;12 Suppl 1:63-8. [PMID: 25938295 DOI: 10.3109/15412555.2015.1021911] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
36 Miravitlles M, Nuñez A, Torres-durán M, Casas-maldonado F, Rodríguez-hermosa JL, López-campos JL, Calle M, Rodríguez E, Esquinas C, Barrecheguren M. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17:346-54. [DOI: 10.1080/15412555.2020.1795824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Cathomas M, Schüller A, Candinas D, Inglin R. Severe postoperative wound healing disturbance in a patient with alpha-1-antitrypsin deficiency: the impact of augmentation therapy. Int Wound J 2015;12:601-4. [PMID: 25818083 DOI: 10.1111/iwj.12419] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
38 Ferrarotti I, Corsico AG, Stolk J, Ottaviani S, Fumagalli M, Janciauskiene S, Iadarola P. Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies. COPD 2017;14:56-65. [PMID: 27827549 DOI: 10.1080/15412555.2016.1241760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Geraghty P, Eden E, Pillai M, Campos M, McElvaney NG, Foronjy RF. α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses. Am J Respir Crit Care Med 2014;190:1229-42. [PMID: 25341065 DOI: 10.1164/rccm.201405-0872OC] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
40 Balbi B, Ferrarotti I, Miravitlles M. Efficacy of augmentation therapy for emphysema associated with α 1 -antitrypsin deficiency: enough is enough. Eur Respir J 2015;47:35-8. [DOI: 10.1183/13993003.01145-2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
41 Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
42 Stockley RA. Alpha1-antitrypsin Review. Clinics in Chest Medicine 2014;35:39-50. [DOI: 10.1016/j.ccm.2013.10.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
43 Mcnulty MJ, Silberstein DZ, Kuhn BT, Padgett HS, Nandi S, Mcdonald KA, Cross CE. Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives. Free Radical Biology and Medicine 2021;163:10-30. [DOI: 10.1016/j.freeradbiomed.2020.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Miravitlles M, Chorostowska-wynimko J, Ferrarotti I, Mcelvaney N, O'hara K, Stolk J, Stockley RA, Turner A, Wilkens M, Greulich T. The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J 2019;53:1900138. [DOI: 10.1183/13993003.00138-2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
45 Low EV, Hughes SM, Zaffarullah S, Kantas D, Stockley RA, Turner AM. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils. Respiration 2018;95:114-21. [PMID: 29253843 DOI: 10.1159/000481867] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
46 Koepke J, Dresel M, Schmid S, Greulich T, Beutel B, Schmeck B, Vogelmeier CF, Janciauskiene S, Koczulla AR. Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO. PLoS One 2015;10:e0117497. [PMID: 25635861 DOI: 10.1371/journal.pone.0117497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
47 Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
48 Chu JH, Zang W, Vukmirovic M, Yan X, Adams T, DeIuliis G, Hu B, Mihaljinec A, Schupp JC, Becich MJ, Hochheiser H, Gibson KF, Chen ES, Morris A, Leader JK, Wisniewski SR, Zhang Y, Sciurba FC, Collman RG, Sandhaus R, Herzog EL, Patterson KC, Sauler M, Strange C, Kaminski N; GRADS Investigators. Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. Thorax 2021;76:134-43. [PMID: 33303696 DOI: 10.1136/thoraxjnl-2019-214301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]